CN1439416A - Agent for protecting womb from profuse menstuation and its preparing method - Google Patents
Agent for protecting womb from profuse menstuation and its preparing method Download PDFInfo
- Publication number
- CN1439416A CN1439416A CN 03112031 CN03112031A CN1439416A CN 1439416 A CN1439416 A CN 1439416A CN 03112031 CN03112031 CN 03112031 CN 03112031 A CN03112031 A CN 03112031A CN 1439416 A CN1439416 A CN 1439416A
- Authority
- CN
- China
- Prior art keywords
- radix
- hemorrhage
- palace
- medicine
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 8
- 238000001035 drying Methods 0.000 claims abstract description 6
- 238000011282 treatment Methods 0.000 claims description 55
- 208000032843 Hemorrhage Diseases 0.000 claims description 30
- 201000010099 disease Diseases 0.000 claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 27
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 24
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 20
- 241000180649 Panax notoginseng Species 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- 239000002994 raw material Substances 0.000 claims description 17
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 16
- 238000005242 forging Methods 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 13
- 235000021419 vinegar Nutrition 0.000 claims description 13
- 239000000052 vinegar Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 230000023597 hemostasis Effects 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000004062 sedimentation Methods 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 3
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 238000003825 pressing Methods 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 229940013618 stevioside Drugs 0.000 claims description 3
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 3
- 235000019202 steviosides Nutrition 0.000 claims description 3
- 229960004793 sucrose Drugs 0.000 claims description 3
- -1 filter Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 59
- 230000000694 effects Effects 0.000 abstract description 47
- 230000008901 benefit Effects 0.000 abstract description 3
- 206010027514 Metrorrhagia Diseases 0.000 abstract description 2
- 239000003433 contraceptive agent Substances 0.000 abstract description 2
- 230000002254 contraceptive effect Effects 0.000 abstract description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 241000902900 cellular organisms Species 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000007781 pre-processing Methods 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 208000007106 menorrhagia Diseases 0.000 description 34
- 208000024891 symptom Diseases 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 12
- 230000027758 ovulation cycle Effects 0.000 description 12
- 230000005906 menstruation Effects 0.000 description 11
- 230000002513 anti-ovulatory effect Effects 0.000 description 9
- 230000002085 persistent effect Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 8
- 210000004914 menses Anatomy 0.000 description 7
- 206010037660 Pyrexia Diseases 0.000 description 6
- 230000010354 integration Effects 0.000 description 6
- 230000003821 menstrual periods Effects 0.000 description 6
- 230000002175 menstrual effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 4
- 238000002651 drug therapy Methods 0.000 description 4
- 206010013781 dry mouth Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 2
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 2
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 235000019606 astringent taste Nutrition 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- SQFSKOYWJBQGKQ-UHFFFAOYSA-N kaempferide Chemical compound C1=CC(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 SQFSKOYWJBQGKQ-UHFFFAOYSA-N 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000002562 urinalysis Methods 0.000 description 2
- TYFJTEPDESMEHE-HNNXBMFYSA-N (3s)-6,8-dihydroxy-3-[2-(4-methoxyphenyl)ethyl]-3,4-dihydroisochromen-1-one Chemical compound C1=CC(OC)=CC=C1CC[C@@H]1OC(=O)C2=C(O)C=C(O)C=C2C1 TYFJTEPDESMEHE-HNNXBMFYSA-N 0.000 description 1
- NQGCBDWQKDAGTK-RYZVSIALSA-N Agrimophol Chemical compound CC1=C(OC)C(C(=O)CCC)=C(O)C(C[C@]2(C)C(C(C(=O)[C@H](C)CC)=C(O)C(C)=C2O)=O)=C1O NQGCBDWQKDAGTK-RYZVSIALSA-N 0.000 description 1
- NQGCBDWQKDAGTK-QDXKXIGTSA-N Agrimophol Natural products O=C(CCC)c1c(OC)c(C)c(O)c(C[C@]2(C)C(=O)C(C(=O)[C@H](CC)C)=C(O)C(C)=C2O)c1O NQGCBDWQKDAGTK-QDXKXIGTSA-N 0.000 description 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WVVSZNPYNCNODU-CJBNDPTMSA-N Ergometrine Natural products C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-CJBNDPTMSA-N 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000207925 Leonurus Species 0.000 description 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 1
- WVVSZNPYNCNODU-XTQGRXLLSA-N Lysergic acid propanolamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)C)C2)=C3C2=CNC3=C1 WVVSZNPYNCNODU-XTQGRXLLSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001523579 Ostrea Species 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 239000009263 Sheng-Hua-Tang Substances 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241001601725 Sthenias Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000005735 Water intoxication Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- TYFJTEPDESMEHE-UHFFFAOYSA-N agrimonolide Natural products C1=CC(OC)=CC=C1CCC1OC(=O)C2=C(O)C=C(O)C=C2C1 TYFJTEPDESMEHE-UHFFFAOYSA-N 0.000 description 1
- UNWAHVGSROASNT-HXNJGWPRSA-N amarolide Chemical compound C[C@H]1C(=O)[C@@H](O)[C@@H]2[C@@]3(C)C(=O)[C@@H](O)C[C@@H](C)[C@@H]3C[C@@H]3[C@@]2(C)[C@H]1CC(=O)O3 UNWAHVGSROASNT-HXNJGWPRSA-N 0.000 description 1
- UNWAHVGSROASNT-UHFFFAOYSA-N amarolide Natural products CC1C(=O)C(O)C2C3(C)C(=O)C(O)CC(C)C3CC3C2(C)C1CC(=O)O3 UNWAHVGSROASNT-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940015047 chorionic gonadotropin Drugs 0.000 description 1
- 210000004252 chorionic villi Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960001405 ergometrine Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000000025 haemostatic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- OXGUCUVFOIWWQJ-HQBVPOQASA-N quercitrin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OXGUCUVFOIWWQJ-HQBVPOQASA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- HSTCACQRSLZQHZ-UHFFFAOYSA-N shinjulactone H Natural products CC1CC(O)C(=O)C2(C)C1CC3OC(=O)CC4C(C)C(O)C(=O)C2C34C HSTCACQRSLZQHZ-UHFFFAOYSA-N 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000003191 uterotonic effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A staltic Chinese medicine in the form of particles for treating functional metrorrhagia and the metrorrhegia cused by contraceptive ring is prepared from 10 Chinese-medicinal materials including oyster shell white peony root, biota tops, rehmannia root, etc through pre-processing, pulverizing, extracting in solvent, purifying, concentrating, drying and granulating. Its advantage is high curative effect.
Description
(1) technical field
The present invention relates to a kind of medicine for the treatment of dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease, specifically is the luxuriant growth palace hemorrhage of feedstock production with the Chinese herbal medicine, the invention still further relates to the preparation method of this medicine.
(2) background technology
Menorrhagia, menostaxis are common gynecological disease, frequently-occurring disease.This type of disease incidence height, and often outbreak repeatedly of many patients, touching difficulty is that a class has a strong impact on the able-bodied disease of women more, brings inconvenience also for simultaneously patient's work, study and daily life.Part patient then can cause other a series of gynaecopathias because of the generation of above-mentioned disease.
According to national intrauterine device tackling key problem cooperative groups: with the major side effects behind the metal intrauterine contraceptive loop is excessive menstruation, and reached at the 400ml that blood volume is many is for putting preceding 8 times of ring, the incidence rate increase by 28% of secondary anemia.In single steel intrauterine device women's the side effect, menorrhagia accounts for 12.53～26.51% on 11 provinces and cities' sampling survey 106608 examples in the whole nation; Menostaxis accounts for 7.21～15.9%; Irregular bleeding accounts for 15.9%; Local inflammation accounts for 5.2～8.7%.Also have lower abdomen discomfort, leukorrhagia to wait until disease in addition.Promptly influence WomanHealth, increased the difficulty of implementation plan child-bearing policy again.
To the treatment of primary disease, following clinical difficult problem puzzlement is arranged at present:
1, uterotonic such as oxytocin, ergometrine can make uterus tetanic property contraction, and effect continues a few hours, and anastalsis is arranged.But can produce side effect such as temporary serious hypertension, water intoxication, unsuitable conventional the application.
2, the employing of operative therapy such as dilatation and curettage more should be prudent, and certain indication is arranged.The antibiotics itself that postoperative must add usefulness has outside the side effect, also can influence suckling.
3, the Chinese patent medicine of present less treatment primary disease, only several not fairly obvious as effects such as motherwort formulation, SHENGHUATANG plus-minus sides, can not satisfy the clinical treatment needs.
(3) summary of the invention
The objective of the invention is to address the above problem, a kind of comprehensive Chinese patent medicine that improves the advantage such as safe and effective, quality controllable of dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD symptom that has is provided, this medicine is carried out pharmacodynamic experiment, the inflammation that this medicine causes foreign body in the animal uterus has the obvious suppression effect, the acute inflammation in animals model is had the swelling of inhibition and transudation, and the infection that causes for ring on the clinical treatment provides foundation; This medicine has inhibitory action in various degree to animal at, isolated uterine smooth muscle, and can obviously resist the uterine smooth muscle that oxytocin causes and shrink strongly: this medicine can obviously shorten bleeding time and clotting time, and can significantly reduce the implicit amount of Fibrinogen, haemostatic effect is remarkable; This medicine is to blood plasma 6-Keto-PGF
1aHave obvious rising effect, improve the endogenous hormone level; This medicine also has significant analgesic activity.
Another object of the present invention provides the compounding method of this treatment dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD medicine.
For achieving the above object, the present invention has adopted following technical scheme:
A kind of luxuriant growth palace hemorrhage with treatment dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease, it is characterized in that: it is made by following raw material, various raw materials by weight ratio:
Concha Ostreae (forging) 4-15 part Radix Paeoniae Alba 2-10 part Cacumen Platycladi (parch to black) 2-10 part
Radix Rehmanniae 2-10 part Fructus Rosae Laevigatae 2-10 part Radix Bupleuri (processed with vinegar) 1-7 part
Radix Notoginseng 0.1-5 part Herba Agrimoniae 2-10 part Cortex Ailanthi 2-10 part
Folium Isatidis 2-10 part
Each raw material also can be by following weight portion proportioning
Concha Ostreae (forging) 3-10 part Radix Paeoniae Alba 3-8 part Cacumen Platycladi (parch to black) 3-8 part
Radix Rehmanniae 3-8 part Fructus Rosae Laevigatae 3-8 part Radix Bupleuri (processed with vinegar) 1-5 part
Radix Notoginseng 0.1-3 part Herba Agrimoniae 3-8 part Cortex Ailanthi 3-8 part
Folium Isatidis 3-8 part
Each raw material also can be by following weight portion proportioning
Concha Ostreae (forging) 6-7 part Radix Paeoniae Alba 3-4 part Cacumen Platycladi (parch to black) 4-5 part
Radix Rehmanniae 3-4 part Fructus Rosae Laevigatae 4-5 part Radix Bupleuri (processed with vinegar) 1-2 part
Radix Notoginseng 0.1-1 part Herba Agrimoniae 4-5 part Cortex Ailanthi 3-4 part
Folium Isatidis 3-4 part
Each raw material weight proportioning is
4.3 parts of Concha Ostreae (forging) 3.2 portions of Cacumen Platycladis of 6.4 portions of Radix Paeoniae Albas (parch to black)
1.5 parts of 4.2 parts of Radix Bupleuri (processed with vinegar) of 3.3 portions of Fructus Rosae Laevigatae of Radix Rehmanniae
3.3 parts of 4.4 parts of Cortex Ailanthis of 0.6 part of Herba Agrimoniae of Radix Notoginseng
3.5 parts of Folium Isatidiss
Said luxuriant growth palace hemorrhage can be a said dosage form on granule, liquid agent or other any pharmaceuticss.
A kind of preparation has the luxuriant growth palace hemorrhage method of treatment dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease, it is characterized in that:
(1) earlier Radix Notoginseng powder is broken into 100 ~ 120 order fine powders;
(2) with the Radix Paeoniae Alba, Radix Bupleuri Diluted Alcohol solution reflux, extract,, discard residue, it is standby that extracting solution reclaims the ethanol rear solution;
(3) Concha Ostreae, Cacumen Platycladi, Radix Rehmanniae, Fructus Rosae Laevigatae, Herba Agrimoniae, Cortex Ailanthi, Folium Isatidis are decocted with water secondary, 2 hours for the first time, 1 hour for the second time, discard residue, the decoction liquor sedimentation is spent the night, and extracts supernatant, merge extracting solution such as the above-mentioned Radix Paeoniae Alba, be condensed into the clear paste of relative density 1.32-1.37 (80 ℃), drying is ground into fine powder;
(4) evenly make granule with dry pressing or boiling granulation method in the back with Radix Notoginseng powder by described mixed.
At concentration of alcohol described in second step is 50%, and reflux, extract, twice is 2 hours for the first time, is 1 hour for the second time, merges extracted twice liquid, filter, and filtrate recycling ethanol, aqueous solution is standby.
In the 4th step, add an amount of dextrine powder, cane sugar powder, lactose powder, stevioside and mix homogeneously.
The solution of the present invention is based on motherland's medical science to dysfunctional uterine hemorrhage and pathogenetic understanding of hemorrhage due to placement of IUD disease and Therapeutic Principle, with reference to modern medicinal agents, pharmaceutical research achievement and form.
In motherland's medical science, to women's warp, produce, have comparatively maturation and scientific understanding, formed the theoretical system of complete uniqueness.Think CHONG meridian being the blood pool, appoint main uterus, through be bloodization, and blood comes from internal organs, annotate in towards times.Because congenital deficiency of kidney-QI, or work, excess of sexual intercourse, injure Liver and kidney, cause dashing appoint deficient, can not the astringency inducing menses, overflow and descending; Or the cloudy deficiency of dividing is arranged, heat lies prostrate the sea of blood; Or the hepatic and renal YIN deficiency, strongly fragrant and heat-transformation; Or keep fit indecorous, scorching in the asthenic fire, the impairment of YIN hematozemia; Or the course of disease with the passing of time, cloudy hinders with blood, and occur that Sthenia is transforming into asthenia or the resembling of simulataneous insufficiency and excessive, finally to become the card of deficiency of YIN heat in blood.Encircle in utero, the visitor takes the status of a sovereign by force, the disturbance menoxenia due to disturbance of CHONG meridian, and the debility of CHONG and REN meridians, menses lose and take the photograph, deficiency of YIN heat in blood in addition, hot forcing blood overflows, and causes menostaxis, menorrhagia.
At above-mentioned etiology and pathogenesis, this is a deficiency of kidney yin, is designated as in the asthenic fire and burns, and menses hold the mistake degree that overflows.Smelting is when Gu Chong hemostasis, nourishing YIN and clearing away heat.Both astringing for hemostasis to be to have filled in its stream, and clearing away heat and cooling blood is with Cheng Qiyuan again, and nourishing YIN and benefiting blood with multiple its old be principle of treatment.All medicines share, Gu Chong hemostasis, nourishing YIN and clearing away heat.Its receipts are taken the photograph and do not stagnate evil, astringency inducing and the gas that do not stagnate takes stopgap measures and do not forget to consolidate, heat clearing away is only used cold and cool.Kidney yin must be mended, irritability Shu Da, and menses must be transferred, and all diseases must be separated.
An important feature of medicine of the present invention is
1, presses the Chinese medical theory prescription, and in conjunction with the pure Chinese medicinal preparation that the modern scientific research achievement is made, have short treating period clinically, the characteristics of instant effect.At commonly encountered diseases, frequently-occurring disease, a sick medicine, outstanding Chinese medicine characteristic.
2, the prescription Chinese crude drug through science extract, purification, improve active constituent content, reduce dose, confirm evident in efficacyly through pharmacodynamics, toxicological experiment, the mice maximum tolerated dose is 280 times of clinical people's consumption; Long term toxicity test is not seen toxicity with 50 times of successive administrations of clinical people's consumption three months, does not see untoward reaction in treatment 300 routine menoxenia patients' clinical observation yet.Reached purpose safe, effective, taking convenience.
3, each step of pharmaceutical preparation of the present invention all has preparation laboratory data and the support of pharmacodynamics preference data, and has formulated the content of effective testing index, thereby guarantees product quality.
4, treat the medicine and the medical procedure of primary disease at present, can not satisfy the clinical treatment needs.
Medicine of the present invention provides a kind of new efficient medicine, increases a kind of powerful mean for clinical with the card medication.
Another important feature of medicine of the present invention is
1, contains a large amount of phenols components in the medicament, comprise agrimophol, paeonol etc., anastalsis is arranged, have in, isolated uterine smooth muscle excitation.
2, also contain a large amount of glycoside compositions in the medicament, comprise Quercitroside, peoniflorin, arasaponin, saikoside, indigo glycosides, iridoid glycoside and ginsenoside's class, paeoniflorin content 〉=20mg/ bag wherein, various pathogens, virus there is inhibitory action, uterine smooth muscle effect and tangible antiinflammatory action.
3, also contain a large amount of flavones ingredients in the medicament, total content reaches 1.2～2.0%, comprises amarolide, Quercetin, agrimonolide, kaempferide etc., and the isolated uterine excitation is arranged; Early pregnancy placental villi nurse tissue is cultivated, promoting sexual gland hormone one chorionic-gonadotropin hormone HCG secretory volume is increased.Also contain polysaccharide and several amino acids constituents.
The clinical use result of medicine of the present invention shows that following advantage is arranged:
1, to select natural plant for use be raw material in the present invention, and each component all meets Pharmacopoeia of the People's Republic of China regulation, press the comprehensive function treatment of Chinese medical theory prescription and treat dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease, no chemical substance.
2, medicine of the present invention through extract, purification, active constituent content height, dose are little, and the strict quality index is arranged, and reach safe and effective, and be quality controllable, the taking convenience requirement.Meet national medical rules.
3, medicine of the present invention provides a kind of new treatment means for treating dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease, replaces Western medicine and operative therapy, avoids its side effect.And its comprehensive function treatment dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease are replenished the blank of such disease treatment.
For showing the effect of Drug therapy dysfunctional uterine hemorrhage of the present invention and hemorrhage due to placement of IUD disease, medicine of the present invention is through the multicenter of 420 routine systems, contrast clinical observation at random, select according to " new Chinese medicine clinical research guideline " version in 1993 draft in, Western medicine diagnose, dialectical standard dysfunctional uterine hemorrhage and the hemorrhage due to placement of IUD disease patient research experiment made a definite diagnosis.
Differential diagnosis in tcm standard (deficiency of YIN heat in blood, syndrome of unconsolidation of Chong and Conception Channels)
Menorrhagia main symptom: menorrhagia.Inferior card: (1) deep red menses, matter is thick or little clot arranged; (2) soreness of the waist and knees; (3) dry mouth and throat; (4) hectic fever is vexed; (5) picture of the tongue: red tongue with lack of fluid, the few or no fur of tongue; (6) pulse condition: count accurately.Main symptom indispensability is wherein doublely seen three of time cards, and is promptly diagnosable.
Menostaxis main symptom: between 8-15 days menstrual period.Inferior card: the same month is through too much.Main symptom indispensability is wherein doublely seen three of time cards, and is promptly diagnosable.
The Western medicine diagnose standard
Menorrhagia: menstrual cycle is normal substantially, and amount is showed increased or surpass 100ml through amount more in the past, surpasses two above persons of menstrual cycle continuously.
Menostaxis: menstrual cycle and normal substantially through amount, the time of passing through surpassed more than 7 days, but was less than 15 days, surpassed two above persons of menstrual cycle continuously.
Instructions of taking: (1) observation group: medicine of the present invention, after coming, promptly begin to take, each 1 bag, every day 2 times, warm boiled water.Serve on for two weeks.(2) matched group: the safe granule in palace (Shanghai No.3 Traditional Chinese Medicine Pharmaceutical Factory's production) promptly begins to take after coming, and each 1 bag, every day 2 times, warm boiled water.Serve on for two weeks.
The course of treatment: 1 month is a course of treatment, observes two courses of treatment.Follow up a case by regular visits to three menstrual cycle after the drug withdrawal.
Result of the test
(1), efficacy assessment standard and foundation: the efficacy assessment standard in the clinical research guideline of menoxenia " new Chinese medicine treatment " issued with reference to Ministry of Health of the People's Republic of China and drafting.
The symptom integral method
Menstrual blood volume: normal 0 minute; Amount was many more in the past, but was less than 100ml 2 minutes; The 100-150ml4 branch; More than 150ml 6 minutes.
Persistent period: normal 0 minute; 8 days-10 days 2 minutes; 11 days-13 days 4 minutes; 14 days-15 days 6 minutes.
The moon stands color: normal 0 minute; Dark red 1 minute; Purple 2 minutes of color; Purple dim or dark purple 3 minutes.
Menstruation quality: normal 0 minute; Thick partially, but do not have clot 1 minute; Thick, a small amount of little clot 2 minutes; Thickness, volume clot 3 minutes;
Waist sacrum symptom: do not have 0 fen; The waist sacrum is aching and limp, accidental 1 minute; The waist sacrum is aching and limp, shows effect repeatedly 2 fens; The waist sacrum is aching and limp, continues outbreak, is difficult for alleviating 3 fens.
Dry mouth and throat: do not have 0 fen; Idol was felt 1 fen; Obviously, still can stand 2 fens; Often outbreak was difficult to stand 3 fens.
Hectic fever: do not have 0 fen; Heating has regularly, the fever of the body of laying one's hand on not very, the persistent period is very short 1 minute; Heating has regularly, the scorching fever of laying one's hand on, long 2 minutes persistent period; Heating has regularly, the high fever like the burning coal over the body of laying one's hand on, and the persistent period is very long 3 minutes.
Vexed: as not have 0 fen; Idol has 1 fen; Often 2 minutes; 3 minutes all day.
Tongue fur: normal 0 minute; Body of the tongue is red partially, few Tianjin of yellow and thin fur 1 minute; The few tongue of red tongue 2 minutes; Red and uncoated tongue 3 minutes.
Efficacy assessment standard
Recovery from illness: treatment back menstruation recovers normal through amount, cycle, menstrual period, other transference cure, and 3 menstrual cycle of drug withdrawal do not recur, and integrated value is 3 minutes.
Produce effects: treatment back menstrual cycle returned to 28 ± 7 days, menorrhagia person has reduced 1/3 or be less than 100ml before amount is than treatment, return in 7 days other transference cure or alleviate menstrual period, 3 menstrual cycle of drug withdrawal do not recur, and integrated value treatment back reduces more than 2/3 than treatment is preceding.
Effectively: treat back menstrual cycle, improvement before amount, ratio treatment in menstrual period, other symptom also than alleviating before the treatment, reduces more than 1/3 than treatment is preceding after the integrated value treatment.
Invalid: treatment back menstrual cycle, do not have through amount, menstrual period and to improve or increase the weight of, integrated value treatment back than treatment before no change or than reduction before the treatment less than 1/3.
Efficacy analysis: the detailed results of this clinical observation, see the following table general curative effect for details
Comparison (%) group n recovery from illness (band) 60 28 (46.67) 17 (28.33) 10 (16.67) 5 (8.33) 2.0526＜0.05 control groups, 30 6 (20.00) 13 (43.33) 7 (23.34) 4 (13.33) observation groups of produce effects enabledisable u p observation group (not band) 90 33 (36.67) 26 (28.89) 25 (27.78) 6 (6.66) 1.9657＜0.05 control groups 30 6 (20.00) 8 (26.67) 12 (40.00) 4 (13.33) of two groups of menostaxis person's general curative effects
As can be seen from the above table: medicine band group cure rate of the present invention reaches 46.67%, obvious effective rate 28.33%, effective percentage 16.67%, inefficiency 8.33%, total obvious effective rate 75.00%, total effective rate 91.67%.The matched group cure rate reaches 20.00%, obvious effective rate 43.33%, effective percentage 23.34%, inefficiency 13.33%, total obvious effective rate 63.33%, total effective rate 86.67%.And two groups of general curative effects are analyzed relatively u=2.0526, p＜0.05 through Ridit.The general curative effect of description medicine of the present invention is excellent than matched group.Medicine anovulatory dysfunctional uterine hemorrhage group cure rate of the present invention reaches 36.67%, obvious effective rate 28.89%, effective percentage 27.78%, inefficiency 6.66%, total obvious effective rate 65.56%, total effective rate 93.33%.The matched group cure rate reaches 20.00%, obvious effective rate 26.67%, effective percentage 40.00%, inefficiency 13.33%, total obvious effective rate 46.67%, total effective rate 86.67%.And two groups of general curative effects are analyzed relatively u=1.9657, p＜0.05 through Ridit.The general curative effect of description medicine of the present invention is excellent than matched group.
Two groups menstrual period too much person's general curative effect comparison (%) group n recovery from illness (band) 90 33 (36.67) 22 (24.44) 27 (30.00) 8 (8.89) 2.3640＜0.05 control groups, 30 4 (13.33) 8 (26.67) 13 (43.33) 5 (16.67) observation groups of produce effects enabledisable u p observation group (not band) 60 24 (40.00) 17 (28.33) 13 (21.67) 6 (10.00) 1.0629＜0.05 control groups 30 9 (30.00) 8 (26.67) 9 (30.00) 4 (13.33)
As can be seen from the above table: medicine band group cure rate of the present invention reaches 36.67%, obvious effective rate 24.44%, effective percentage 30.00%, inefficiency 8.89%, total obvious effective rate 61.11%, total effective rate 91.11%.The matched group cure rate reaches 13.33%, obvious effective rate 26.67%, effective percentage 43.33%, inefficiency 16.67%, total obvious effective rate 40.00%, total effective rate 83.33%.And two groups of general curative effects are analyzed relatively u=2.3640, p＜0.05 through Ridit.The general curative effect of description medicine of the present invention is excellent than matched group.Medicine anovulatory dysfunctional uterine hemorrhage group cure rate of the present invention reaches 40.00%, obvious effective rate 28.33%, effective percentage 21.67%, inefficiency 10.00%, total obvious effective rate 68.33%, total effective rate 90.00%.The matched group cure rate reaches 30.00%, obvious effective rate 26.67%, effective percentage 30.00%, inefficiency 13.33%, total obvious effective rate 56.67%, total effective rate 86.67%.And two groups of general curative effects are analyzed relatively u=1.0629, p＜0.05 through Ridit.The general curative effect of description medicine of the present invention is excellent than matched group.
The curative effect of two groups of menostaxis person state of an illness integrations compares (%) before and after the treatment
(the treatment back of x ± the s) (observation group's (band) 60 14.95 ± 3.92 3.07 ± 4.31 of x ± s) before the group n treatment
△ △ ※ ※Matched group 30 14.47 ± 4.49 5.63 ± 4.66
△ △Observation group's (anovulatory dysfunctional uterine hemorrhage) 90 12.94 ± 3.94 3.07 ± 3.89
△ △ ※ ※Matched group 30 13.03 ± 4.63 5.47 ± 4.46
△ △
Annotate: with relatively use before the treatment
△ △Expression P＜0.01; With relatively use after the treatment of control group
※ ※Expression P＜0.01.
As can be seen from the above table: before and after two groups of treatments the curative effect of menostaxis person state of an illness integration is more all had utmost point significant difference, P＜0.01; Medicine of the present invention is being better than the safe groups of grains in palace, P＜0.01 again aspect the curative effect of menostaxis.
The curative effect of two groups of menorrhagia person's state of an illness integrations compares (%) before and after the treatment
(the treatment back of x ± the s) (observation group's (band) 90 13.14 ± 4.04 3.51 ± 3.98 of x ± s) before the group n treatment
△ △ ※Matched group 30 12.77 ± 3.10 5.23 ± 2.76
△ △Observation group's (not band) 60 13.40 ± 3.79 3.53 ± 4.26
△ △Matched group 30 13.77 ± 3.87 4.30 ± 4.49
△ △
Annotate: with relatively use before the treatment
△ △Expression P＜0.01; With relatively use after the treatment of control group
※Expression P＜0.05.
As can be seen from the above table: before and after two groups of treatments the curative effect of menorrhagia person's state of an illness integration is more all had utmost point significant difference, P＜0.01; Be better than the safe groups of grains in palace aspect the menorrheal curative effect that medicine of the present invention causes at band, P＜0.05.But there was no significant difference aspect two groups of menorrheal curative effects that cause at anovulatory dysfunctional uterine hemorrhage, P＞0.05.
The curative effect that symptom and sign changes before and after the treatment relatively
The curative effect of two groups of treatment front and back menorrhagia (band) symptom and sign variations relatively
Before the treatment
After the treatment
In the group
Between group
Sign n
(example) ++++++-++++++-u p u p menstrual blood volume observation group 90 29 56 5019 43 37 10.2419＜0.01 1.2408＞0.05
30 6 21 3022 18 8 5.0982＜0.01 persistent period of matched group observation group 90 05 30 55 007 83 3.6650＜0.01 0.3652＞0.05
Matched group 30 008 22 001 29 1.5653＞0.05 month is through color observation group 90 6 26 55 004 33 53 7.6886＜0.01 1.8562＞0.05
Matched group 30 0 11 17 200 20 10 3.4286＜0.01 month is through quality observation group 90 5 32 51 204 29 57 8.3757＜0.01 0.8398＞0.05
Matched group 30 0 12 15 3009 21 4.8300＜0.01 waist sacrum observation of symptoms group 90 4 28 53 503 28 59 8.0458＜0.01 2.1240＜0.05
Matched group 30 2 21 6102 16 12 5.1429＜0.01 dry mouth and throat observation group 90 1 15 37 37 01 10 79 5.6061＜0.01 0.1126＞0.05
Matched group 30 06 14 10 007 23 3.2199＜0.01 hectic fever observation group 90 03 31 56 015 84 3.5918＜0.01 0.2769＞0.05
Matched group 30 019 20 001 29 2.0199＜0.01 vexed observation group 90 3 21 48 18 03 16 71 7.1995＜0.01 1.7071＞0.05
Matched group 30 09 15 600 13 17 3.3317＜0.01 picture of the tongue observation group 90 0 18 70 202 30 58 7.8033＜0.01 1.7284＞0.05
Matched group 30 0 13 13 401 16 13 3.4659＜0.01
As can be seen from the above table: menorrhagia (band) symptom and sign all has extremely significant improvement effect before and after the Drug therapy of the present invention, p＜0.01 or p＜0.05, and on waist sacrum symptom, be excellent than matched group, p＜0.05.
The curative effect of two groups of treatment front and back menostaxis (anovulatory dysfunctional uterine hemorrhage) symptom and sign variations relatively
Before the treatment
After the treatment
In the group
Between group
Sign n
(example) ++++++-++++++-u p u p menstrual blood volume observation group 90 08 36 46 01 17 72 3.5000＜0.01 1.1015＞0.05
30 067 17 002 28 2.5491＜0.01 persistent period of matched group observation group 90 22 53 15 005 34 51 10.292＜0.01 0.3652＞0.05
Matched group 30 66 18 016 12 11 2.8175＞0.05 month is through color observation group 90 5 28 47 10 04 29 57 7.1995＜0.01 3.4476＜0.01
Matched group 30 0 19 11 007 15 8 3.3392＜0.01 month is through quality observation group 90 5 30 48 703 23 64 8.3284＜0.01 3.3959＜0.01
Matched group 30 0 22 8006 14 10 4.1740＜0.01 waist sacrum observation of symptoms group 90 5 23 56 606 28 56 7.1406＜0.01 0.5782＞0.05
Matched group 30 2 16 11 101 13 16 5.0312＜0.01 dry mouth and throat observation group 90 1 15 53 21 024 84 8.0759＜0.01 0.8277＞0.05
Matched group 30 12 17 10 023 25 3.1827＜0.01 hectic fever observation group 90 05 39 46 015 84 4.8857＜0.01 0.5356＞0.05
Matched group 30 02 10 18 004 26 1.8485＞0.05 vexed observation group 90 2 20 42 26 02 13 75 6.6214＜0.01 0.8185＞0.05
Matched group 30 02 19 9017 22 2.8696＜0.01 picture of the tongue observation group 90 0 18 68 402 24 64 8.1706＜0.01 2.4952＜0.05
Matched group 30 0 11 19 004 13 13 3.4063＜0.01
As can be seen from the above table: menostaxis (anovulatory dysfunctional uterine hemorrhage) symptom and sign all has extremely significant improvement effect before and after the Drug therapy of the present invention, p＜0.01, and on persistent period, menstruation color, menstruation quality, picture of the tongue, be excellent than matched group, p＜0.01 or p＜0.05.
Model case: thank so-and-so, woman, 27 years old, the work of Overseas Chinese Hotel, Changchun, No. 23, case numbering.
This patient goes to a doctor because of the menstrual blood volume showed increased half a year, patient's readme menstruation in puerperal is gone over the past half year again, and the more preceding showed increased of menstruation is at every turn with sanitary towel's 3 bags (30), pass through 8 days to 9 days beginnings only at every turn, deep red menses, thick menses, but do not have clot, the companion sees soreness of the waist and knees, the time have vexed, the few Tianjin of red tongue, tongue fur BOHUANG, thready and rolling pulse.Be menstrual cycle first day when examining, got rid of organic disease, blood, routine urinalysis through B ultrasonic and gynecologial examination, electrocardiogram, liver, renal function procuratorial work are normal, FIB3.4g/L, doctor trained in Western medicine examine for: dysfunctional uterine bleeding (the ovulation type is arranged), the traditional Chinese medical science are examined and are menorrhagia (deficiency of YIN blood-heat type).Medicine of the present invention is given in throwing, one time 1 bag, 2 times on the one, oral, be connected with the back of taking medicine in two weeks to next menstrual onset, patient's readme is through the more preceding minimizing of amount, but still is many more in the past, with sanitary towel's 2 bags (20), 8 old name for the Arabian countries in the Middle Easts of passing through are clean, the menstruation quality as before, but the more preceding improvement of soreness of the waist and knees, surplus disease such as preceding.Continue clothes two weeks of medicine-feeding again, all transfer to normally through amount, phase, color, matter, surplus disease disappears.Check blood, routine urinalysis after the drug withdrawal, electrocardiogram, liver, renal function are all normal, and FIB3.3g/L follows up a case by regular visits to three menstrual cycle, does not see recurrence, clinical cure.Do not find untoward reaction at viewing duration.
The clinical efficacy of medicine of the present invention
Test statistics shows: the clinical efficacy of Drug therapy dysfunctional uterine hemorrhage of the present invention and hemorrhage due to placement of IUD disease patient 300 examples is satisfied, its menostaxis band group cure rate reaches 46.67%, obvious effective rate reaches 28.33%, effective percentage reaches 16.67%, inefficiency is 8.33%, total obvious effective rate reaches 75.00%, and total effective rate reaches 91.67%; The matched group cure rate reaches 20.00%, and obvious effective rate reaches 43.33%, and effective percentage reaches 23.34%, and inefficiency is 13.33%, and total obvious effective rate reaches 63.33%, and total effective rate reaches 86.67%, but two groups of general curative effects are analyzed relatively p＜0.05 through Ridit.The general curative effect that medicine of the present invention is described is better than matched group.Medicine menostaxis anovulatory dysfunctional uterine hemorrhage group cure rate of the present invention reaches 36.67%, and obvious effective rate reaches 28.89%, and effective percentage reaches 27.78%, and inefficiency is 6.66%, and total obvious effective rate reaches 65.56%, and total effective rate reaches 93.33%; The matched group cure rate reaches 20.00%, and obvious effective rate reaches 26.67%, and effective percentage reaches 40.00%, and inefficiency is 13.33%, and total obvious effective rate reaches 46.67%, and total effective rate reaches 86.67%, two group of general curative effect and analyzes relatively p＜0.05 through Ridit.The general curative effect that medicine of the present invention is described is better than matched group.Medicine menorrhagia band group cure rate of the present invention reaches 36.67%, and obvious effective rate reaches 24.44%, and effective percentage reaches 30.00%, and inefficiency is 8.89%, and total obvious effective rate reaches 61.11%, and total effective rate reaches 91.11%; The matched group cure rate reaches 13.33%, and obvious effective rate reaches 26.67%, and effective percentage reaches 43.33%, and inefficiency is 16.67%, and total obvious effective rate reaches 40.00%, and total effective rate reaches 83.33%, two group of general curative effect and analyzes relatively p＜0.05 through Ridit.The general curative effect that medicine of the present invention is described is better than matched group.Medicine menorrhagia anovulatory dysfunctional uterine hemorrhage group cure rate of the present invention reaches 40.00%, and obvious effective rate reaches 28.33%, and effective percentage reaches 21.67%, and inefficiency is 10.00%, and total obvious effective rate reaches 68.33%, and total effective rate reaches 90.00%; The matched group cure rate reaches 30.00%, and obvious effective rate reaches 26.67%, and effective percentage reaches 30.00%, and inefficiency is 13.33%, and total obvious effective rate reaches 56.67%, and total effective rate reaches 86.67%, two group of general curative effect and analyzes relatively p＞0.05 through Ridit.The general curative effect that medicine of the present invention is described is consistent with matched group.It is to menostaxis, menorrheal state of an illness integration, symptom and sign all improves significantly, p＜0.01 or p＜0.05, and menstruation persistent period of menstruation persistent period, picture of the tongue and the menostaxis anovulatory dysfunctional uterine hemorrhage group of the state of an illness integration of menostaxis band group and menostaxis band group, menstruation color, menstruation quality, picture of the tongue etc. to aspect all be better than matched group, p＜0.01 or p＜0.05.
The above results explanation: medicine of the present invention is the Chinese medicine for the treatment of a kind of determined curative effect of the dysfunctional uterine hemorrhage of deficiency of YIN blood-heat type menorrhagia and menostaxis symptom and hemorrhage due to placement of IUD patient clinically, is worthy to be popularized, uses.
(4) specific embodiment
The invention will be further described below in conjunction with embodiment.
Embodiment one:
A kind of luxuriant growth palace hemorrhage with treatment dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease, it is characterized in that: it is made by following raw material, various raw materials by weight ratio:
Concha Ostreae (forging) 4-15 part Radix Paeoniae Alba 2-10 part Cacumen Platycladi (parch to black) 2-10 part
Radix Rehmanniae 2-10 part Fructus Rosae Laevigatae 2-10 part Radix Bupleuri (processed with vinegar) 1-7 part
Radix Notoginseng 0.1-5 part Herba Agrimoniae 2-10 part Cortex Ailanthi 2-10 part
Folium Isatidis 2-10 part
Embodiment two:
Each raw material by weight ratio
Concha Ostreae (forging) 3-10 part Radix Paeoniae Alba 3-8 part Cacumen Platycladi (parch to black) 3-8 part
Radix Rehmanniae 3-8 part Fructus Rosae Laevigatae 3-8 part Radix Bupleuri (processed with vinegar) 1-5 part
Radix Notoginseng 0.1-3 part Herba Agrimoniae 3-8 part Cortex Ailanthi 3-8 part
Folium Isatidis 3-8 part
Embodiment three:
Wherein each raw material weight proportioning is
Concha Ostreae (forging) 6-7 part Radix Paeoniae Alba 3-4 part Cacumen Platycladi (parch to black) 4-5 part
Radix Rehmanniae 3-4 part Fructus Rosae Laevigatae 4-5 part Radix Bupleuri (processed with vinegar) 1-2 part
Radix Notoginseng 0.1-1 part Herba Agrimoniae 4-5 part Cortex Ailanthi 3-4 part
Folium Isatidis 3-4 part
Embodiment four:
Wherein each raw material weight proportioning is
4.3 parts of Concha Ostreae (forging) 3.2 portions of Cacumen Platycladis of 6.4 portions of Radix Paeoniae Albas (parch to black)
1.5 parts of 4.2 parts of Radix Bupleuri (processed with vinegar) of 3.3 portions of Fructus Rosae Laevigatae of Radix Rehmanniae
3.3 parts of 4.4 parts of Cortex Ailanthis of 0.6 part of Herba Agrimoniae of Radix Notoginseng
Folium Isatidis 3-4 part
Embodiment five:
Wherein each raw material weight proportioning is
4.3 parts of Concha Ostreae (forging) 3.2 portions of Cacumen Platycladis of 6.4 portions of Radix Paeoniae Albas (parch to black)
1.5 parts of 4.2 parts of Radix Bupleuri (processed with vinegar) of 3.3 portions of Fructus Rosae Laevigatae of Radix Rehmanniae
3.3 parts of 4.4 parts of Cortex Ailanthis of 0.6 part of Herba Agrimoniae of Radix Notoginseng
3.5 parts of Folium Isatidiss
Use for convenient, the present invention can be a said dosage form on granule, liquid agent or other any pharmaceuticss, is granule in the present invention.
Preparation method of the present invention is:
(1) earlier Radix Notoginseng powder is broken into 100 ~ 120 order fine powders;
(2) with the Radix Paeoniae Alba, Radix Bupleuri Diluted Alcohol solution reflux, extract,, discard residue, it is standby that extracting solution reclaims the ethanol rear solution;
(3) Concha Ostreae, Cacumen Platycladi, Radix Rehmanniae, Fructus Rosae Laevigatae, Herba Agrimoniae, Cortex Ailanthi, Folium Isatidis are decocted with water secondary, 2 hours for the first time, 1 hour for the second time, discard residue, the decoction liquor sedimentation is spent the night, and extracts supernatant, merge extracting solution such as the above-mentioned Radix Paeoniae Alba, be condensed into the clear paste of relative density 1.32-1.37 (80 ℃), drying is ground into fine powder;
(4) evenly make granule with dry pressing or boiling granulation method in the back with Radix Notoginseng powder by described mixed.
With 50% alcohol reflux secondary, 2 hours for the first time, 1 hour for the second time, the merging secondary raffinate filtered in second step, filtrate recycling ethanol, and aqueous solution is standby; All the other Concha Ostreaes, Cacumen Platycladi, Radix Rehmanniae, Fructus Rosae Laevigatae, Herba Agrimoniae, Cortex Ailanthi, Folium Isatidis decoct with water secondary, and 2 hours for the first time, 1 hour for the second time, merge decoction liquor, filter the filtrate standing over night, supernatant is extracted in sedimentation, merges backflow such as the above-mentioned Radix Paeoniae Alba, be condensed into thick paste, drying under reduced pressure, dried cream powder is broken into fine powder, with Radix Notoginseng powder and an amount of dextrine powder, cane sugar powder, lactose powder, stevioside mixing, granulate, drying, promptly.
Claims (8)
1, a kind of luxuriant growth palace hemorrhage with treatment dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease, it is characterized in that: it is made by following raw material, various raw materials by weight ratio:
Concha Ostreae (forging) 4-15 part Radix Paeoniae Alba 2-10 part Cacumen Platycladi (parch to black) 2-10 part
Radix Rehmanniae 2-10 part Fructus Rosae Laevigatae 2-10 part Radix Bupleuri (processed with vinegar) 1-7 part
Radix Notoginseng 0.1-5 part Herba Agrimoniae 2-10 part Cortex Ailanthi 2-10 part
Folium Isatidis 2-10 part
2, luxuriant growth according to claim 1 palace hemorrhage, it is characterized in that: each raw material is optimum ratio by weight
Concha Ostreae (forging) 3-10 part Radix Paeoniae Alba 3-8 part Cacumen Platycladi (parch to black) 3-8 part
Radix Rehmanniae 3-8 part Fructus Rosae Laevigatae 3-8 part Radix Bupleuri (processed with vinegar) 1-5 part
Radix Notoginseng 0.1-3 part Herba Agrimoniae 3-8 part Cortex Ailanthi 3-8 part
Folium Isatidis 3-8 part
3, luxuriant growth palace hemostasis granules agent according to claim 1, it is characterized in that: wherein the further preferred weight proportioning of each raw material is
Concha Ostreae (forging) 6-7 part Radix Paeoniae Alba 3-4 part Cacumen Platycladi (parch to black) 4-5 part
Radix Rehmanniae 3-4 part Fructus Rosae Laevigatae 4-5 part Radix Bupleuri (processed with vinegar) 1-2 part
Radix Notoginseng 0.1-1 part Herba Agrimoniae 4-5 part Cortex Ailanthi 3-4 part
Folium Isatidis 3-4 part
4, luxuriant growth according to claim 1 palace hemorrhage, it is characterized in that: wherein the best by weight proportioning of each raw material is
4.3 parts of Concha Ostreae (forging) 3.2 portions of Cacumen Platycladis of 6.4 portions of Radix Paeoniae Albas (parch to black)
1.5 parts of 4.2 parts of Radix Bupleuri (processed with vinegar) of 3.3 portions of Fructus Rosae Laevigatae of Radix Rehmanniae
3.3 parts of 4.4 parts of Cortex Ailanthis of 0.6 part of Herba Agrimoniae of Radix Notoginseng
3.5 parts of Folium Isatidiss
5, according to claim 1,2,3 or 4 described luxuriant growth palace hemorrhages, it is characterized in that: said luxuriant growth palace hemorrhage can be a said dosage form on granule, liquid agent or other any pharmaceuticss.
6, a kind of preparation method with luxuriant growth palace hemorrhage of treatment dysfunctional uterine hemorrhage and hemorrhage due to placement of IUD disease is characterized in that:
(1) earlier Radix Notoginseng powder is broken into 100 ~ 120 order fine powders;
(2) with the Radix Paeoniae Alba, Radix Bupleuri Diluted Alcohol solution reflux, extract,, discard residue, it is standby that extracting solution reclaims the ethanol rear solution;
(3) Concha Ostreae, Cacumen Platycladi, Radix Rehmanniae, Fructus Rosae Laevigatae, Herba Agrimoniae, Cortex Ailanthi, Folium Isatidis are decocted with water secondary, 2 hours for the first time, 1 hour for the second time, discard residue, the decoction liquor sedimentation is spent the night, and extracts supernatant, merge extracting solution such as the above-mentioned Radix Paeoniae Alba, be condensed into the clear paste of relative density 1.32-1.37 (80 ℃), drying is ground into fine powder;
(4) evenly make granule with dry pressing or boiling granulation method in the back with Radix Notoginseng powder by described mixed.
7, preparation method according to claim 6 is characterized in that: at concentration of alcohol described in second step is 50%, and reflux, extract, twice is 2 hours for the first time, is 1 hour for the second time, merges extracted twice liquid, filter, and filtrate recycling ethanol, aqueous solution is standby.
8, preparation method according to claim 6 is characterized in that: in the 4th step, add an amount of dextrine powder, cane sugar powder, lactose powder, stevioside and mix homogeneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03112031 CN1197607C (en) | 2003-03-24 | 2003-03-24 | Agent for protecting womb from profuse menstuation and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03112031 CN1197607C (en) | 2003-03-24 | 2003-03-24 | Agent for protecting womb from profuse menstuation and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1439416A true CN1439416A (en) | 2003-09-03 |
| CN1197607C CN1197607C (en) | 2005-04-20 |
Family
ID=27796902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03112031 Expired - Lifetime CN1197607C (en) | 2003-03-24 | 2003-03-24 | Agent for protecting womb from profuse menstuation and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1197607C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856431A (en) * | 2010-06-02 | 2010-10-13 | 南京中医药大学 | Medicament for treating liver-kidney yin deficiency type anovulatory dysfunctional uterine bleeding, and preparation method and application thereof |
| CN104587219A (en) * | 2015-02-15 | 2015-05-06 | 山东省文登整骨医院 | Traditional Chinese medicine for treating functional uterine bleeding |
| CN104825495A (en) * | 2015-04-19 | 2015-08-12 | 青岛大学 | Oyster extract and application thereof in medicaments for promoting postpartum uterine contraction |
-
2003
- 2003-03-24 CN CN 03112031 patent/CN1197607C/en not_active Expired - Lifetime
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856431A (en) * | 2010-06-02 | 2010-10-13 | 南京中医药大学 | Medicament for treating liver-kidney yin deficiency type anovulatory dysfunctional uterine bleeding, and preparation method and application thereof |
| CN101856431B (en) * | 2010-06-02 | 2011-08-31 | 南京中医药大学 | Medicament for treating liver-kidney yin deficiency type anovulatory dysfunctional uterine bleeding, and preparation method and application thereof |
| CN104587219A (en) * | 2015-02-15 | 2015-05-06 | 山东省文登整骨医院 | Traditional Chinese medicine for treating functional uterine bleeding |
| CN104825495A (en) * | 2015-04-19 | 2015-08-12 | 青岛大学 | Oyster extract and application thereof in medicaments for promoting postpartum uterine contraction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1197607C (en) | 2005-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1768812A (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN100346819C (en) | Chinese medicinal preparation for treating prostate disease and its production method | |
| CN1698815A (en) | Chinese medicinal composite ointment, its preparation process, cataplasm thereof and method for preparing the same | |
| CN1212134C (en) | Compound Chinese medicine prepn for treating urinary system infection and prostatitis and its prepn process | |
| CN1724022A (en) | Compound traditional Chinese medicinal prepn. for preventing and treating uterus abnormal bleeding disease, and its prepn. method | |
| CN1785292A (en) | Medicine for treating flooding and spotting and its preparation method | |
| CN1287830C (en) | Chinese traditional medicine compound preparation for treating gynecopathy and preparation method thereof | |
| CN1706435A (en) | Chinese medicine composition for treating premenstrual stage stress syndrome an dits prepn process | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN100368008C (en) | Chinese medicine for treating gynopathy and its preparing process | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN1439416A (en) | Agent for protecting womb from profuse menstuation and its preparing method | |
| CN1203876C (en) | Medicine for curing postpartum subinvolution of uterus and its preparation method | |
| CN1240412C (en) | Chinese medicine compound preparation for treating piles and preparing process thereof | |
| CN101073655A (en) | Chinese medicine for treating pityriasis roasea, psoriasis and drug eruption | |
| CN1820770A (en) | Chinese medicine composition for treating apoplexy and its preparing method | |
| CN1262296C (en) | Medicine composition, preparing method and use for preparing gynacecopathia medicine | |
| CN1270762C (en) | Cough stopping and asthma relieving medicine and its preparation | |
| CN1148217C (en) | Chinese medicine for treating chronic bronchitis | |
| CN1509741A (en) | Chinese medicinal preparation for preventing herpes virus and preparing method thereof | |
| CN1679734A (en) | Chinese medicine composition for treating prostatitis and preparation thereof | |
| CN1899581A (en) | Medicinal composition for treating qi stagnation and cold stasis stomach-ache and its preparing method and use | |
| CN1772239A (en) | Chinese medicine prepn for treating vaginitis and cervicitis | |
| CN1541691A (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1186052C (en) | Medicine for treatment of pelvic inflammation, its preparation and preparing method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: YAO JIANGUO Free format text: FORMER OWNER: YU SHAOHUA Effective date: 20060407 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20060407 Address after: Siming District of Xiamen city of Fujian province Xianyue road 361012 No. 597 1002 Patentee after: Tao Jianguo Address before: 250104 Shandong Province, Ji'nan city is industrial technology demonstration area Taisho biotechnology company Patentee before: Yu Shaohua |
|
| ASS | Succession or assignment of patent right |
Owner name: TIANJIN ZHONGSHENGHAITIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: YAO JIANGUO Effective date: 20100726 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 361012 1002, NO.597, XIANYUE ROAD, SIMING DISTRICT, XIAMEN CITY, FUJIAN PROVINCE TO: 300350 NO.1, DAGANG SOUTH ROAD, SHUANGGANG TOWN, JINNAN DISTRICT, TIANJIN CITY |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100726 Address after: 300350, No. 1 South Port Road, double Town, Jinnan District, Tianjin Patentee after: TIANJIN HORUS C&K PHARMACEUTICAL Co.,Ltd. Address before: Siming District of Xiamen city of Fujian province Xianyue road 361012 No. 597 1002 Patentee before: Tao Jianguo |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Agent for protecting womb from profuse menstuation and its preparing method Effective date of registration: 20120726 Granted publication date: 20050420 Pledgee: Bank of Shanghai Limited by Share Ltd. Tianjin branch Pledgor: TIANJIN HORUS C&K PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000405 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20130710 Granted publication date: 20050420 Pledgee: Bank of Shanghai Limited by Share Ltd. Tianjin branch Pledgor: TIANJIN HORUS C&K PHARMACEUTICAL Co.,Ltd. Registration number: 2012990000405 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Agent for protecting womb from profuse menstuation and its preparing method Effective date of registration: 20130726 Granted publication date: 20050420 Pledgee: Bank of Shanghai Limited by Share Ltd. Tianjin branch Pledgor: TIANJIN HORUS C&K PHARMACEUTICAL Co.,Ltd. Registration number: 2013120000024 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20140728 Granted publication date: 20050420 Pledgee: Bank of Shanghai Limited by Share Ltd. Tianjin branch Pledgor: TIANJIN HORUS C&K PHARMACEUTICAL Co.,Ltd. Registration number: 2013120000024 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Agent for protecting womb from profuse menstuation and its preparing method Effective date of registration: 20140821 Granted publication date: 20050420 Pledgee: Bank of Shanghai Limited by Share Ltd. Tianjin branch Pledgor: TIANJIN HORUS C&K PHARMACEUTICAL Co.,Ltd. Registration number: 2014120000046 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20151215 Granted publication date: 20050420 Pledgee: Bank of Shanghai Limited by Share Ltd. Tianjin branch Pledgor: TIANJIN HORUS C&K PHARMACEUTICAL Co.,Ltd. Registration number: 2014120000046 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| CX01 | Expiry of patent term |
Granted publication date: 20050420 |
|
| CX01 | Expiry of patent term |